Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
CRAIG BROWN: The killer who wants to be Donald Trump's running mate
Dog's dining table act shocks family and leads to speculation he was a 'human in a past life'
China's new Hugo Award winner draws inspiration from history and traditional culture
Mideast countries disappointed by U.S. veto on Palestinian bid for full UN membership
Finnish hacker imprisoned for accessing thousands of psychotherapy records and demanding ransoms
Prosecutors to make history with opening statements in hush money case against Trump
Stone carvings found inside cave of China's Longmen Grottoes
China urges U.S. to formulate universal data security rules to enable orderly, free data flows
EDEN CONFIDENTIAL: Prince Harry's army friend JJ Chalmers urges Kate to talk about cancer
Now Brits holidaying in Tenerife could be slapped with a tourist tax, Canary Islands leader warns
Trainer and Brehm can find a few perks amid New Orleans disappointment
China's BYD adds new dealership in Tokyo